Certolizumab

Certolizumab Struktur
428863-50-7
CAS-Nr.
428863-50-7
Englisch Name:
Certolizumab
Synonyma:
Cimzia;Cdp870;Pha 738144;Unii-umd07X179e;CERTOLIZUMAB PEGOL;Research Grade Certolizumab(DHB94401);(2S)-1-((2S)-6-aMino-2-((hydroxy(4-phenylbutyl)phosphoryl)oxy)hexanoyl)pyrrolidine-2-carboxylic acid;Immunoglobulin, anti-(human tumor necrosis factor alpha) fab' fragment (human-mouse monoclonal cdp870 heavy chain), disulfide with human-mouse monoclonal cdp870 light chain, pegylated
CBNumber:
CB52497315
Summenformel:
C24H22F3N
Molgewicht:
381.4333896
MOL-Datei:
428863-50-7.mol

Certolizumab Eigenschaften

storage temp. 
Store at -20°C

Sicherheit

Giftige Stoffe Daten 428863-50-7(Hazardous Substances Data)

Certolizumab Chemische Eigenschaften,Einsatz,Produktion Methoden

Beschreibung

Certolizumab pegol, a tumor necrosis factor α(TNF-α) blocker, was launched for the treatment of moderate-to-severe Crohn’s disease. It is specifically indicated for reducing signs and symptoms and maintaining clinical response in adult patients who have had an inadequate response to conventional therapy. Certolizumab pegol is the third anti-TNF-α biologic to be marketed for this indication behind infliximab (Remicade) and adalimumab (Humira). Certolizumab pegol is a recombinant, humanized antibody Fab’ fragment linked to approximately 40 kDa polyethylene glycol (PEG). The Fab’ fragment is composed of a light chain with 214 amino acids and a heavy chain with 229 amino acids. It is manufactured in E.coli and is subsequently subjected to purification and conjugation to PEG, to generate certolizumab pegol. The addition of PEG moiety significantly enhances the plasma half-life of the antibody, allowing for less frequent dosing. Certolizumab pegol neutralizes both soluble and membrane-associated forms of human TNF-a. It binds to human TNF-a with slightly higher affinity (KD 0.09 nM) than infliximab (KD 0.23 nM) and adalimumab (KD 0.16 nM). In addition, in cellular assays, certolizumab pegol is more potent in preventing TNF-a-induced killing of L929 fibroblasts than infliximab and adalimumab (IC50 0.35 ng/mL versus 5 and 6 ng/mL, 592 Shridhar Hegde and Michelle Schmidt respectively).

Verwenden

Treatment of rheumatoid arthritis and inflammatory bowel disease.

Nebenwirkungen

The most common adverse reactions with certolizumab were upper respiratory infections (20%), urinary tract infections (7%), and anthralgias (6%). TNF-a blockers as a class have been linked to increased risk of opportunistic infections and malignancy. Tuberculosis, invasive fungal infections, and other serious infections have occurred in patients receiving certolizumab pegol, and the drug label contains a black-box warning of the risk.

Certolizumab Upstream-Materialien And Downstream Produkte

Upstream-Materialien

Downstream Produkte


Certolizumab Anbieter Lieferant Produzent Hersteller Vertrieb Händler.

Global( 7)Lieferanten
Firmenname Telefon E-Mail Land Produktkatalog Edge Rate
Aladdin Scientific
+1-833-552-7181
sales@aladdinsci.com United States 52927 58
shanghai cooperpharm co.,LTD . +86-021-58975553
sales@cooperpharm.com China 1210 56
Shanghai Han-Xiang Chemical Co., Ltd. 15971444841
amber@biochempartner.com China 3063 58
Wuhan Chemstan Biotechnology Co., Ltd. 027-65317797 15926423062
422450190@qq.com China 10055 58
AntibodySystem 027-65279366 18162686757
biolab-reagents@atagenix.com China 9816 58
Shanghai jerryxing Biomedical Technology Co., Ltd 17721492509
643638326@qq.com China 5347 58

  • Cdp870
  • Cimzia
  • Immunoglobulin, anti-(human tumor necrosis factor alpha) fab' fragment (human-mouse monoclonal cdp870 heavy chain), disulfide with human-mouse monoclonal cdp870 light chain, pegylated
  • Pha 738144
  • Unii-umd07X179e
  • (2S)-1-((2S)-6-aMino-2-((hydroxy(4-phenylbutyl)phosphoryl)oxy)hexanoyl)pyrrolidine-2-carboxylic acid
  • CERTOLIZUMAB PEGOL
  • Research Grade Certolizumab(DHB94401)
  • 428863-50-7
Copyright 2019 © ChemicalBook. All rights reserved